Last reviewed · How we verify
NCT06555315
Pilot Trial Investigating Every Other Day Dosing of Oral Iron in Premature Infants (IQONic)
NA trial testing 6 mg/kg of oral iron as ferrous sulfate administered every other day. in Very Low Birth Weight Infant in 100 participants. Currently enrolling.
28 March 2026
Quick facts
| Lead sponsor | CHRISTUS Health |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 100 |
| Start date | 1 August 2024 |
| Primary completion | 28 March 2026 |
| Estimated completion | 28 March 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 6 mg/kg of oral iron as ferrous sulfate administered every other day.
- 6 mg/kg of oral iron as ferrous sulfate administered every day.
Conditions studied
- Very Low Birth Weight Infant — all drugs for Very Low Birth Weight Infant →
- Premature Infants — all drugs for Premature Infants →
- Anemia of Prematurity — all drugs for Anemia of Prematurity →
- Iron Deficiency, Anaemia in Children — all drugs for Iron Deficiency, Anaemia in Children →
Sponsor
CHRISTUS Health — full company profile →
Who can join
Adults 26 Weeks to 32 Weeks, any sex, with Very Low Birth Weight Infant or Premature Infants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study focuses on determining if daily versus every-other-day (EOD) oral iron at the same dose per kilogram per day will achieve similar incidence of iron replete status at 36 weeks post-menstrual age in premature neonates
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06555315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Very Low Birth Weight Infant
Currently open trials in the same condition.
- NCT05308134 — Individualized Fortification of Human Milk for Infants Born ≤ 1250 g (MaxiMoM-InForM) · NA · recruiting
- NCT04640805 — Targeted Fortification of Pasteurized Donor Human Milk · NA · active not recruiting
- NCT05399667 — Assessment of Body Composition in Premature Children Submitted to an Early Stimulation Program · active not recruiting
- NCT04239508 — Swiss Neonatal Network & Follow-up Group · recruiting
Other CHRISTUS Health trials
Trials by the same sponsor.
- NCT06726811 — Droperidol and QTc Interval Changes in ED Patients · recruiting
- NCT06589284 — Skin Glue Versus Suture for Securing Radial Arterial Lines · NA · completed
- NCT04869579 — Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients. · Phase 2 · unknown
- NCT06059417 — Foam Tape Allergy a Sticky Situation · NA · completed
- NCT06437301 — End Tidal CO2 and Masks: Is There a Correlation? · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06555315 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CHRISTUS Health
- Last refreshed: 15 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06555315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing